| scholarly article | Q13442814 |
| P2093 | author name string | Jaume Sauleda | |
| Antonio Oliver | |||
| María D Maciá | |||
| José L Pérez | |||
| Bernat Togores | |||
| David Blanquer | |||
| P2860 | cites work | Costs and Benefits of High Mutation Rates: Adaptive Evolution of Bacteria in the Mouse Gut | Q56944626 |
| Highly Variable Mutation Rates in Commensal and Pathogenic Escherichia coli | Q56944671 | ||
| Small-Colony Variants of Pseudomonas aeruginosa in Cystic Fibrosis | Q57542653 | ||
| Epidemiology Of Chronic Pseudomonas aeruginosa Infections In Cystic Fibrosis | Q59334968 | ||
| Pulsed-Field Gel Electrophoresis | Q59509098 | ||
| Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis | Q67574773 | ||
| Computed tomography of bronchiectasis | Q70403810 | ||
| Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens | Q72246081 | ||
| Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis | Q74341827 | ||
| Hypermutation as a Factor Contributing to the Acquisition of Antimicrobial Resistance | Q79162727 | ||
| Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen | Q22122393 | ||
| The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants | Q28492576 | ||
| Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing | Q29614699 | ||
| Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper | Q29614960 | ||
| Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia | Q29615286 | ||
| Lung infections associated with cystic fibrosis | Q30080000 | ||
| Escherichia coli mutator genes | Q33539352 | ||
| Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis | Q33961155 | ||
| Mutator clones of Neisseria meningitidis in epidemic serogroup A disease | Q34028018 | ||
| Evolution of high mutation rates in experimental populations of E. coli | Q34429727 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| Nosocomial infections in adult intensive-care units | Q35157647 | ||
| The role of mutators in the emergence of antibiotic-resistant bacteria | Q35177659 | ||
| Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 | ||
| Pseudomonal infections in patients with COPD: epidemiology and management | Q35627613 | ||
| Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis | Q36528124 | ||
| Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains | Q37421041 | ||
| Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections | Q37598703 | ||
| Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients | Q39955018 | ||
| Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort | Q40412050 | ||
| Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies | Q40477935 | ||
| Transformation of Pseudomonas aeruginosa by electroporation | Q40540293 | ||
| Emergence of phenotypic variants upon mismatch repair disruption in Pseudomonas aeruginosa | Q40557981 | ||
| Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion | Q40968218 | ||
| Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test | Q43627836 | ||
| Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis | Q43754593 | ||
| Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? | Q43874264 | ||
| High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains | Q44195004 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| High mutation frequencies among Escherichia coli and Salmonella pathogens | Q48057867 | ||
| Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. | Q53592119 | ||
| Efficacy of aerosolized tobramycin in patients with cystic fibrosis. | Q54237890 | ||
| Role of mutator alleles in adaptive evolution. | Q54564129 | ||
| Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. | Q55066725 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| P304 | page(s) | 3382-3386 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections | |
| P478 | volume | 49 |
| Q30844823 | A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. |
| Q37340607 | A global view of antibiotic resistance |
| Q37622415 | A non-canonical mismatch repair pathway in prokaryotes |
| Q33987501 | A quorum sensing regulated small volatile molecule reduces acute virulence and promotes chronic infection phenotypes. |
| Q51489925 | A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. |
| Q35816112 | Acinetobacter baumannii Repeatedly Evolves a Hypermutator Phenotype in Response to Tigecycline That Effectively Surveys Evolutionary Trajectories to Resistance |
| Q33743249 | Adaptation of iron homeostasis pathways by a Pseudomonas aeruginosa pyoverdine mutant in the cystic fibrosis lung |
| Q36369411 | An analogy between the evolution of drug resistance in bacterial communities and malignant tissues |
| Q38679480 | An update on pediatric bronchiectasis |
| Q99555879 | Antibiotic Resistance Characteristics of Pseudomonas aeruginosa Isolated from Keratitis in Australia and India |
| Q38392008 | Antibiotic discovery: combatting bacterial resistance in cells and in biofilm communities. |
| Q41937031 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| Q37356533 | Antimicrobial resistance: its emergence and transmission |
| Q89018240 | Applications of genomics to slow the spread of multidrug-resistant Neisseria gonorrhoeae |
| Q33564290 | Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections |
| Q36933558 | Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa |
| Q43153453 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants |
| Q37794342 | Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance |
| Q42930592 | Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection |
| Q38207078 | Chronic pulmonary pseudomonal infection in patients with cystic fibrosis: A model for early phase symbiotic evolution |
| Q43253659 | Chronic respiratory infections by mucoid carbapenemase-producing Pseudomonas aeruginosa strains, a new potential public health problem |
| Q34948367 | Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. |
| Q43205983 | Co-existence of multidrug-resistant and -susceptible strains of Pseudomonas aeruginosa from a single clinical isolate |
| Q35914177 | Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model |
| Q35350270 | Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections. |
| Q44918690 | Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms |
| Q34999026 | Development of genomic resources for a thraustochytrid pathogen and investigation of temperature influences on gene expression |
| Q36095041 | Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro |
| Q45812779 | Draft Genome Sequence of the Mucoid Pseudomonas aeruginosa Clinical Isolate PA34. |
| Q31029779 | Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. |
| Q38202864 | Ecological and temporal constraints in the evolution of bacterial genomes. |
| Q37876027 | Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance |
| Q41833848 | Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators |
| Q34509793 | Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa |
| Q43006550 | Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa |
| Q37896674 | Emergence and spread of antibiotic resistance following exposure to antibiotics |
| Q46608208 | Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy |
| Q37105688 | Emergence of epidemic multidrug-resistant Enterococcus faecium from animal and commensal strains |
| Q41280370 | Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators |
| Q38665048 | Enhanced membrane disruption and antibiotic action against pathogenic bacteria by designed histidine-rich peptides at acidic pH |
| Q42221354 | Environmental stress and antibiotic resistance in food-related pathogens |
| Q33886303 | Epistatic roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in coping with reactive oxygen species-induced DNA damage |
| Q90230125 | Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling |
| Q35426622 | Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. |
| Q34082906 | Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. |
| Q40052272 | Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study |
| Q28238561 | Evolution of mutation rates in bacteria |
| Q33911762 | Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone |
| Q35960653 | Evolutionary origins of invasive populations |
| Q45897898 | Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa |
| Q41903957 | Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients |
| Q84061280 | Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients |
| Q38414823 | Fighting microbial drug resistance: a primer on the role of evolutionary biology in public health |
| Q42375984 | Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa |
| Q41366386 | Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation |
| Q30278439 | Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains |
| Q39656697 | Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections |
| Q37342706 | Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients |
| Q36667671 | Hypermutable Pseudomonas aeruginosa in Cystic fibrosis patients from two Brazilian cities. |
| Q44350722 | Hypermutable Staphylococcus aureus strains present at high frequency in subclinical bovine mastitis isolates are associated with the development of antibiotic resistance |
| Q37922538 | Hypermutation and stress adaptation in bacteria |
| Q89766030 | Hypermutator Pseudomonas aeruginosa exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients |
| Q48009346 | Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease |
| Q90192659 | Impact of Strain Competition on Bacterial Resistance in Immunocompromised Populations |
| Q42560500 | Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. |
| Q42909082 | Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. |
| Q42210567 | Induction of mycobacterial resistance to quinolone class antimicrobials |
| Q35879111 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| Q39218893 | Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria |
| Q38962871 | Involvement of stress-related genes polB and PA14_46880 in biofilm formation of Pseudomonas aeruginosa |
| Q38010784 | Levofloxacin for the treatment of respiratory tract infections |
| Q57166411 | Long-Term Colonization Dynamics of Enterococcus faecalis in Implanted Devices in Research Macaques |
| Q36756563 | Lytic phages obscure the cost of antibiotic resistance in Escherichia coli |
| Q21296756 | Megacities as sources for pathogenic bacteria in rivers and their fate downstream |
| Q58164270 | Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients |
| Q57169588 | Meropenem combined with ciprofloxacin combats hypermutable from respiratory infections of cystic fibrosis patients |
| Q36313186 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals |
| Q41461270 | Molecular identification and genotyping of Pseudomonas aeruginosa isolated from cystic fibrosis and non-cystic fibrosis patients with bronchiectasis. |
| Q34117477 | Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections |
| Q37678002 | Mutators and hypermutability in bacteria: the Escherichia coli paradigm |
| Q36887819 | Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa |
| Q50044377 | Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model. |
| Q38309969 | PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. |
| Q34297656 | Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients |
| Q38006032 | Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections |
| Q37002813 | Predicting antibiotic resistance |
| Q38273318 | Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review. |
| Q28299966 | Pseudomonas aeruginosa biofilms in cystic fibrosis |
| Q37924864 | Pseudomonas aeruginosa in a hydropathic facility: diversity, susceptibility and imipenem resistance mutation. |
| Q35084559 | Pseudomonas aeruginosa: resistance to the max |
| Q37373050 | Recent advances in the microbiology of respiratory tract infection in cystic fibrosis |
| Q36109214 | Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs |
| Q36295397 | Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation |
| Q42717931 | Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa |
| Q64979740 | Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics. |
| Q44034811 | Role of a short tandem leucine/arginine repeat in strong mutator phenotype acquisition in a clinical isolate of Salmonella Typhimurium |
| Q33482815 | Role of mutation in Pseudomonas aeruginosa biofilm development. |
| Q35939649 | Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. |
| Q39281402 | Surfactant protein A blocks recognition of Pseudomonas aeruginosa by CKAP4/P63 on airway epithelial cells. |
| Q40324438 | The GO system prevents ROS-induced mutagenesis and killing in Pseudomonas aeruginosa |
| Q33386642 | The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection |
| Q52313185 | The Versatile Mutational Resistome of Pseudomonas aeruginosa. |
| Q33856134 | The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa |
| Q28492495 | The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa |
| Q38300820 | The problems of antibiotic resistance in cystic fibrosis and solutions |
| Q51663672 | The role of natural environments in the evolution of resistance traits in pathogenic bacteria. |
| Q38898519 | The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates |
| Q64068057 | Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents—How P. aeruginosa Can Escape Antibiotics |
| Q45118441 | Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis |
| Q33285539 | Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain |
| Q82979670 | [Carbapenemases in Pseudomonas spp] |
| Q51594842 | [Chronic bronchial infection: the problem of Pseudomonas aeruginosa]. |
| Q82598514 | [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery] |
| Q83386827 | [Microbiological diagnosis of bronchopulmonary colonization-infection in cystic fibrosis] |
Search more.